![Martin Lehr](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Lehr
Fondateur chez
CONTEXT THERAPEUTICS INC.
Fortune : 3 M $ au 31/05/2026
Profil
Martin A. Lehr is the founder of Context Therapeutics LLC, founded in 2016, serving as Chief Executive Officer & Director.
Mr. Lehr is the founder of Context Therapeutics, Inc., founded in 2015, serving as President, Chief Executive Officer & Director.
Current jobs include Director at The Biobreak Organization, Inc. since 2009, Independent Director at Praesidia Biotherapeutics, Inc. since 2020, and Board Member at CureDuchenne Ventures LLC since 2019.
Former job includes Senior Associate at OUP Management Co. LLC.
Education includes a graduate degree from The Trustees of Columbia University in The City of New York in 2009 and an undergraduate degree from the University of Pennsylvania in 2006.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 13/04/2026 | 1 079 891 ( 1,18 % ) | 3 M $ | 31/05/2026 |
Postes actifs de Martin Lehr
| Sociétés | Poste | Début |
|---|---|---|
| CONTEXT THERAPEUTICS INC. | Fondateur | 01/04/2015 |
Context Therapeutics LLC
 Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures hormone-responsive cancer drugs | Fondateur | 01/01/2016 |
The Biobreak Organization, Inc. | Directeur/Membre du Conseil | 01/01/2009 |
Praesidia Biotherapeutics, Inc.
 Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapy to overcome drug addiction | Directeur/Membre du Conseil | 01/11/2020 |
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements. | Directeur/Membre du Conseil | 01/05/2019 |
Anciens postes connus de Martin Lehr
| Sociétés | Poste | Fin |
|---|---|---|
OUP Management Co. LLC
 OUP Management Co. LLC Investment ManagersFinance Osage Partners invests in companies located across the globe primarily in the United States. The firm targets companies operating in the fields of technology and life science sectors includes software, hardware, climate tech, therapeutics, medtech, diagnostics, research tools enabled services companies. It provide financing for pre-seed to late stage capital requirements with investment size ranges from USD1 million to USD20 million. It acts as a lead or co-lead investor. | Analyste en capital-investissement | - |
Formation de Martin Lehr
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
98
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OUP Management Co. LLC
OUP Management Co. LLC Investment ManagersFinance Osage Partners invests in companies located across the globe primarily in the United States. The firm targets companies operating in the fields of technology and life science sectors includes software, hardware, climate tech, therapeutics, medtech, diagnostics, research tools enabled services companies. It provide financing for pre-seed to late stage capital requirements with investment size ranges from USD1 million to USD20 million. It acts as a lead or co-lead investor. | Finance |
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures seeks investment opportunities located in the United States. The firm targets companies operating in the fields of health technology companies. It provides financing for early-stage capital requirements. | Finance |
Context Therapeutics LLC
Context Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures hormone-responsive cancer drugs | Health Technology |
Context Therapeutics, Inc.
 Context Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops treatment options for women living with hormone-dependent cancer | Health Technology |
The Biobreak Organization, Inc. | |
Praesidia Biotherapeutics, Inc.
Praesidia Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Provides therapy to overcome drug addiction | Health Services |
